Oxygenta Pharmaceutical Ltd
Un-audited Financial Results for the Quarter ended 30.06.2026.
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 27 Jul 2026, 06:12 PM IST · BSE ID: 784ef85f-c211-4fa4-b2d1-113ff9f80ddf
View Original BSE Filing (PDF)
💡
In Simple Terms
The company released its financial results for April-June 2026, showing Rs. 3,699.69 Lakhs in revenue and a loss.
🤖 AI Summary
- Oxygenta Pharmaceutical reported revenue from operations of Rs. 3,699.69 Lakhs for Q1 FY27.
- Net loss for the quarter ended June 30, 2026, was Rs. 210.37 Lakhs.
- M/s. PCR & Associates were appointed as Cost Auditors for the Financial Year 2026-27.
- The Annual General Meeting for FY 2025-26 will be held on Friday, August 21, 2026.
- The Board also approved the re-constitution of the POSH Committee effective July 27, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
3,699.69 Lakhs
Revenue from operations (Q1 FY26)
1,513.47 Lakhs
Net Profit / (Loss) for the period (Q1 FY27)
(210.37) Lakhs
Net Profit / (Loss) for the period (Q1 FY26)
(610.61) Lakhs
Basic EPS (Q1 FY27)
(0.57)
🏢 How This Affects the Company
The company's revenue from operations increased to Rs. 3,699.69 Lakhs for Q1 FY27 compared to Rs. 1,513.47 Lakhs in the corresponding quarter of the previous year.
The net loss for the period decreased to Rs. 210.37 Lakhs from Rs. 610.61 Lakhs in the prior comparable quarter. The company availed Rs. 399 Lakhs under the Emergency Credit Line Guarantee Scheme.
The appointment of new Cost Auditors for FY 2026-27 and the re-constitution of the POSH Committee reflect ongoing governance and compliance activities.
The company continues to report a net loss, indicating ongoing financial challenges. The note regarding active work to identify MSME creditors suggests potential compliance or payment processing complexities.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are informed of the upcoming Annual General Meeting on August 21, 2026, which they may attend via Video Conferencing/OAVM.
👤
Who Is Affected
All shareholders are affected by the company's financial performance and corporate governance decisions, including the appointment of cost auditors and the re-constitution of the POSH committee.
🔍
Management Signal
The Board's actions in approving Q1 FY27 results, appointing cost auditors, and scheduling the AGM indicate a focus on financial reporting, compliance, and corporate governance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Outcome of Annual General Meeting on August 21, 2026.
Q2 FY27 financial results — check revenue and loss trends.
Updates on MSME creditor identification process.
MEDIUM RISK
The company continues to report losses, despite revenue growth, indicating ongoing financial performance challenges.
💡 Investor Takeaway
Oxygenta Pharmaceutical reported Q1 FY27 revenue from operations of Rs. 3,699.69 Lakhs, up from Rs. 1,513.47 Lakhs in Q1 FY26. The net loss for the quarter ended June 30, 2026, was Rs. 210.37 Lakhs, an improvement from a Rs. 610.61 Lakhs loss in the prior comparable quarter.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from operations significantly increased to Rs. 3,699.69 Lakhs in Q1 FY27 from Rs. 1,513.47 Lakhs in Q1 FY26.
- Net loss for the quarter ended June 30, 2026, reduced to Rs. 210.37 Lakhs from Rs. 610.61 Lakhs in the previous comparable quarter.
⚠️ Concerns
- The company reported a net loss of Rs. 210.37 Lakhs for the quarter ended June 30, 2026.
- The company's total expenses of Rs. 3,952.75 Lakhs exceeded its total revenue of Rs. 3,702.02 Lakhs for Q1 FY27.
📅 Company Track Record
Past filings indicated a Board meeting on July 25, 2026, to approve the Q1 FY27 unaudited financial results, which was completed as per this filing on July 27, 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Oxygenta Pharmaceutical's revenue from operations for the quarter ended June 30, 2026?
Oxygenta Pharmaceutical's revenue from operations for the quarter ended June 30, 2026, was Rs. 3,699.69 Lakhs.
What was the net profit or loss for Oxygenta Pharmaceutical in Q1 FY27?
The net loss for Oxygenta Pharmaceutical for the quarter ended June 30, 2026 (Q1 FY27), was Rs. 210.37 Lakhs.
Which firm was appointed as Cost Auditors for Oxygenta Pharmaceutical for FY 2026-27?
M/s. PCR & Associates, Cost Accountants, were appointed as Cost Auditors for Oxygenta Pharmaceutical Limited for the Financial Year 2026-27.
When is Oxygenta Pharmaceutical's Annual General Meeting for FY 2025-26 scheduled?
The Annual General Meeting for Oxygenta Pharmaceutical for the FY 2025-26 is scheduled to be held on Friday, August 21, 2026, at 10:30 a.m. through Video Conferencing/other Audio-Visual Means.
What was Oxygenta Pharmaceutical's Loss Before Tax for the quarter ended June 30, 2026?
The Loss Before Tax for Oxygenta Pharmaceutical for the quarter ended June 30, 2026, was Rs. 250.73 Lakhs.
Questions based on this BSE filing only. For information purposes.